Advances in adoptive cellular therapy for colorectal cancer: A narrative review

Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries

Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21660 · Cited by 108,699 · see citing works

PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer

Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989 · see citing works

The blockade of immune checkpoints in cancer immunotherapy

Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838 · see citing works

Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma

Neelapu, S. S., Locke, F. L., Bartlett, N. L., Lekakis, L. J., Miklos, D. B., Jacobson, C. A., Braunschweig, I., Oluwole, O. O., Siddiqi, T., Lin, Y., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1707447 · Cited by 6,030 · see citing works

A guide to cancer immunotherapy: from T cell basic science to clinical practice

Waldman, A. D., Fritz, J. M., & Lenardo, M. J. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-020-0306-5 · Cited by 4,154 · see citing works

Chimeric antigen receptor–modified T cells in chronic lymphoid leukemia

Porter, D. L., Levine, B. L., Kalos, M., Bagg, A., & June, C. H. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103849 · Cited by 3,565 · see citing works

Cancer regression in patients after transfer of genetically engineered lymphocytes

Morgan, R. A., Dudley, M. E., Wunderlich, J. R., Hughes, M. S., Yang, J. C., Sherry, R. M., Royal, R. E., Topalian, S. L., Kammula, U. S., Restifo, N. P., et al. (2006) · Science · doi:10.1126/science.1129003 · Cited by 2,603 · see citing works

Adoptive cell transfer as personalized immunotherapy for human cancer

Rosenberg, S. A., & Restifo, N. P. (2015) · Science · doi:10.1126/science.aaa4967 · Cited by 2,492 · see citing works

Use of Tumor-Infiltrating Lymphocytes and Interleukin-2 in the Immunotherapy of Patients with Metastatic Melanoma

Rosenberg, S. A., Packard, B. S., Aebersold, P. M., Solomon, D., Topalian, S. L., Toy, S. T., Simon, P., Lotze, M. T., Yang, J. C., Seipp, C. A., et al. (1988) · New England Journal of Medicine · doi:10.1056/nejm198812223192527 · Cited by 2,389 · see citing works

Durable Complete Responses in Heavily Pretreated Patients with Metastatic Melanoma Using T-Cell Transfer Immunotherapy

Rosenberg, S. A., Yang, J. C., Sherry, R. M., Kammula, U. S., Hughes, M. S., Phan, G. Q., Citrin, D. E., Restifo, N. P., Robbins, P. F., Wunderlich, J. R., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0116 · Cited by 2,145 · see citing works

A New Approach to the Adoptive Immunotherapy of Cancer with Tumor-Infiltrating Lymphocytes

Rosenberg, S. A., Spiess, P. J., & Lafrenière, R. (1986) · Science · doi:10.1126/science.3489291 · Cited by 1,888 · see citing works

4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors

Long, A. H., Haso, W. M., Shern, J. F., Wanhainen, K. M., Murgai, M., Ingaramo, M., Smith, J. P., Walker, A. J., Kohler, M. E., Venkateshwara, V. R., et al. (2015) · Nature Medicine · doi:10.1038/nm.3838 · Cited by 1,815 · see citing works

Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia

Porter, D. L., Hwang, W.-T., Frey, N. V., Lacey, S. F., Shaw, P. A., Loren, A. W., Bagg, A., Marcucci, K. T., Shen, A., Gonzalez, V., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aac5415 · Cited by 1,729 · see citing works

Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors.

Eshhar, Z., Waks, T., Gross, G., & Schindler, D. G. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.2.720 · Cited by 1,668 · see citing works

Tumor Regression in Patients With Metastatic Synovial Cell Sarcoma and Melanoma Using Genetically Engineered Lymphocytes Reactive With NY-ESO-1

Robbins, P. F., Morgan, R. A., Feldman, S. A., Yang, J. C.-H., Sherry, R. M., Dudley, M. E., Wunderlich, J. R., Nahvi, A. V., Helman, L. J., Mackall, C. L., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.32.2537 · Cited by 1,635 · see citing works

Emerging functions of the EGFR in cancer

Sigismund, S., Avanzato, D., & Lanzetti, L. (2017) · Molecular Oncology · doi:10.1002/1878-0261.12155 · Cited by 1,497 · see citing works

The basic principles of chimeric antigen receptor (CAR) design

Sadelain, M., Brentjens, R., & Rivière, I. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0548 · Cited by 1,423 · see citing works

Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen

Johnson, L. A., Morgan, R. A., Dudley, M. E., Cassard, L., Yang, J. C.-H., Hughes, M. S., Kammula, U. S., Royal, R. E., Sherry, R. M., Wunderlich, J. R., et al. (2009) · Blood · doi:10.1182/blood-2009-03-211714 · Cited by 1,421 · see citing works

T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer

Tran, E., Robbins, P. F., Lu, Y.-C., Prickett, T. D., Gartner, J. J., Jia, L., Pasetto, A., Zheng, Z., Ray, S., Groh, E. M., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1609279 · Cited by 1,368 · see citing works

Adoptive Cell Therapy for Patients With Metastatic Melanoma: Evaluation of Intensive Myeloablative Chemoradiation Preparative Regimens

Dudley, M. E., Yang, J. C., Sherry, R. M., Hughes, M. S., Royal, R. E., Kammula, U. S., Robbins, P. F., Huang, J., Citrin, D. E., Leitman, S. F., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.5449 · Cited by 1,334 · see citing works

The carcinoembryonic antigen (CEA) family: structures, suggested functions and expression in normal and malignant tissues

Hammarström, S. (1999) · Seminars in Cancer Biology · doi:10.1006/scbi.1998.0119 · Cited by 1,303 · see citing works

Cancer Regression and Neurological Toxicity Following Anti-MAGE-A3 TCR Gene Therapy

Morgan, R. A., Chinnasamy, N., Abate‐Daga, D., Gros, A., Robbins, P. F., Zheng, Z., Dudley, M. E., Feldman, S. A., Yang, J. C., Sherry, R. M., et al. (2013) · Journal of Immunotherapy · doi:10.1097/cji.0b013e3182829903 · Cited by 1,155 · see citing works

The Principles of Engineering Immune Cells to Treat Cancer

Lim, W. A., & June, C. H. (2017) · Cell · doi:10.1016/j.cell.2017.01.016 · Cited by 1,084 · see citing works

Engineered T cells: the promise and challenges of cancer immunotherapy

Fesnak, A. D., June, C. H., & Levine, B. L. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.97 · Cited by 1,074 · see citing works

Clinical implications of T cell exhaustion for cancer immunotherapy

Chow, A., Perica, K., Klebanoff, C. A., & Wolchok, J. D. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00689-z · Cited by 1,044 · see citing works

T Cells Targeting Carcinoembryonic Antigen Can Mediate Regression of Metastatic Colorectal Cancer but Induce Severe Transient Colitis

Parkhurst, M. R., Yang, J. C.-H., Langan, R. C., Dudley, M. E., Nathan, D.-A. N., Feldman, S. A., Davis, J. L., Morgan, R. A., Merino, M. J., Sherry, R. M., et al. (2010) · Molecular Therapy · doi:10.1038/mt.2010.272 · Cited by 1,025 · see citing works

Recent advances in CAR T-cell toxicity: Mechanisms, manifestations and management

Brudno, J. N., & Kochenderfer, J. N. (2018) · Blood Reviews · doi:10.1016/j.blre.2018.11.002 · Cited by 909 · see citing works

NY-ESO-1–specific TCR–engineered T cells mediate sustained antigen-specific antitumor effects in myeloma

Rapoport, A. P., Stadtmauer, E. A., Binder-Scholl, G. K., Goloubeva, O. G., Vogl, D. T., Lacey, S. F., Badros, A. Z., Garfall, A. L., Weiss, B. M., Finklestein, J. M., et al. (2015) · Nature Medicine · doi:10.1038/nm.3910 · Cited by 857 · see citing works

CAR T Cells for Solid Tumors: New Strategies for Finding, Infiltrating, and Surviving in the Tumor Microenvironment

Martinez, M. C., & Moon, E. K. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00128 · Cited by 855 · see citing works

Adoptive immunotherapy for cancer: building on success

Gattinoni, L., Powell, D. J., Rosenberg, S. A., & Restifo, N. P. (2006) · Nature reviews. Immunology · doi:10.1038/nri1842 · Cited by 841 · see citing works

Immune recognition of somatic mutations leading to complete durable regression in metastatic breast cancer

Zacharakis, N., Chinnasamy, H., Black, M. A., Xu, H., Lu, Y., Zheng, Z., Pasetto, A., Langhan, M. M., Shelton, T. E., Prickett, T. D., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0040-8 · Cited by 770 · see citing works

TRUCKs: the fourth generation of CARs

Chmielewski, M. M., & Abken, H. (2015) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2015.1046430 · Cited by 750 · see citing works

Complete Regression of Metastatic Cervical Cancer After Treatment With Human Papillomavirus–Targeted Tumor-Infiltrating T Cells

Stevanović, S., Draper, L. M., Langhan, M. M., Campbell, T. E., Kwong, M. L. M., Wunderlich, J. R., Dudley, M. E., Yang, J. C., Sherry, R. M., Kammula, U. S., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.58.9093 · Cited by 682 · see citing works

Antibody-modified T cells: CARs take the front seat for hematologic malignancies

Maus, M. V., Grupp, S. A., Porter, D., & June, C. H. (2014) · Blood · doi:10.1182/blood-2013-11-492231 · Cited by 617 · see citing works

Review on Epidermal Growth Factor Receptor (EGFR) Structure, Signaling Pathways, Interactions, and Recent Updates of EGFR Inhibitors

Sabbah, D. A., Hajjo, R., & Sweidan, K. (2020) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026620666200303123102 · Cited by 606 · see citing works

NKG2D Receptor and Its Ligands in Host Defense

Lanier, L. L. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0098 · Cited by 599 · see citing works

Molecular Pathways: Targeting B7-H3 (CD276) for Human Cancer Immunotherapy

Picarda, E., Ohaegbulam, K. C., & Zang, X. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2428 · Cited by 582 · see citing works

Transfer of specificity by murine α and β T-cell receptor genes

Dembić, Z., Haas, W., Weiß, S., McCubrey, J. A., Kiefer, H., von Boehmer, H., & Steinmetz, M. (1986) · Nature · doi:10.1038/320232a0 · Cited by 579 · see citing works

Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors

Kochenderfer, J., & Rosenberg, S. (2013) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2013.46 · Cited by 467 · see citing works

Colorectal Cancer Immunotherapy: Options and Strategies

Johdi, N. A., & SUKOR, N. F. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01624 · Cited by 457 · see citing works

Phase I Escalating-Dose Trial of CAR-T Therapy Targeting CEA+ Metastatic Colorectal Cancers

Zhang, C., Wang, Z., Yang, Z., Wang, M., Li, S., Li, Y., Zhang, R., Xiong, Z., Wei, Z., Shen, J., et al. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.03.010 · Cited by 454 · see citing works

Lifileucel, a Tumor-Infiltrating Lymphocyte Therapy, in Metastatic Melanoma

Sarnaik, A. A., Hamid, O., Khushalani, N. I., Lewis, K. D., Medina, T. M., Kluger, H. M., Thomas, S. S., Domingo‐Musibay, E., Pavlick, A. C., Whitman, E. D., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.21.00612 · Cited by 451 · see citing works

Identifying and Targeting Human Tumor Antigens for T Cell-Based Immunotherapy of Solid Tumors

Leko, V., & Rosenberg, S. A. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.07.013 · Cited by 449 · see citing works

Teaching an old dog new tricks: next-generation CAR T cells

Tokarew, N. J. A., Ogonek, J., Endres, S., von Bergwelt‐Baildon, M., & Kobold, S. (2018) · British Journal of Cancer · doi:10.1038/s41416-018-0325-1 · Cited by 444 · see citing works

Tumor-Infiltrating Lymphocytes Expressing the Tissue Resident Memory Marker CD103 Are Associated with Increased Survival in High-Grade Serous Ovarian Cancer

Webb, J. R., Milne, K., Watson, P. H., deLeeuw, R. J., & Nelson, B. H. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1877 · Cited by 435 · see citing works

Tumor-infiltrating lymphocyte treatment for anti-PD-1-resistant metastatic lung cancer: a phase 1 trial

Creelan, B., Wang, C., Teer, J. K., Toloza, E. M., Yao, J., Kim, S., Landin, A. M., Mullinax, J. E., Saller, J. J., Saltos, A. N., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01462-y · Cited by 434 · see citing works

Engineered T Cell Therapy for Cancer in the Clinic

Zhao, L., & Cao, Y. J. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02250 · Cited by 414 · see citing works

Engineering and Design of Chimeric Antigen Receptors

Guedan, S., Calderon, H., Posey, A., & Maus, M. V. (2018) · Molecular Therapy: Methods & Clinical Development · doi:10.1016/j.omtm.2018.12.009 · Cited by 407 · see citing works

CAR-T cells: the long and winding road to solid tumors

D’Aloia, M. M., Zizzari, I. G., Sacchetti, B., Pierelli, L., & Alimandi, M. (2018) · Cell Death and Disease · doi:10.1038/s41419-018-0278-6 · Cited by 403 · see citing works

B7-H3 and B7x are highly expressed in human prostate cancer and associated with disease spread and poor outcome

Zang, X., Thompson, R. H., Al-Ahmadie, H. A., Serio, A. M., Reuter, V. E., Eastham, J. A., Scardino, P. T., Sharma, P., & Allison, J. P. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0709802104 · Cited by 401 · see citing works

Adoptive Transfer of Tumor-Infiltrating Lymphocytes in Patients with Metastatic Melanoma: Intent-to-Treat Analysis and Efficacy after Failure to Prior Immunotherapies

Besser, M. J., Shapira‐Frommer, R., Itzhaki, O., Treves, A. J., Zippel, D. B., Levy, D., Kubi, A., Shoshani, N., Zikich, D., Ohayon, Y., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0380 · Cited by 387 · see citing works

Emerging Cellular Therapies for Cancer

Guedan, S., Ruella, M., & June, C. H. (2018) · Annual Review of Immunology · doi:10.1146/annurev-immunol-042718-041407 · Cited by 386 · see citing works

Expression and function of epithelial cell adhesion molecule EpCAM: where are we after 40 years?

Gires, O., Pan, M., Schinke, H., Canis, M., & Baeuerle, P. A. (2020) · Cancer and Metastasis Reviews · doi:10.1007/s10555-020-09898-3 · Cited by 355 · see citing works

Cancer stem cell surface markers on normal stem cells

Kim, W., & Ryu, C. J. (2017) · BMB Reports · doi:10.5483/bmbrep.2017.50.6.039 · Cited by 338 · see citing works

CD133-directed CAR T cells for advanced metastasis malignancies: A phase I trial

Wang, Y., Chen, M., Wu, Z., Tong, C., Dai, H., Guo, Y., Liu, Y., Huang, J., Lv, H., Luo, C., et al. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1440169 · Cited by 338 · see citing works

Safety, tumor trafficking and immunogenicity of chimeric antigen receptor (CAR)-T cells specific for TAG-72 in colorectal cancer

Hege, K. M., Bergsland, E. K., Fisher, G. A., Nemunaitis, J. J., Warren, R. S., McArthur, J. G., Lin, A., Schlom, J., June, C. H., & Sherwin, S. A. (2017) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-017-0222-9 · Cited by 325 · see citing works

T cell receptor‐based cancer immunotherapy: Emerging efficacy and pathways of resistance

Chandran, S. S., & Klebanoff, C. A. (2019) · Immunological Reviews · doi:10.1111/imr.12772 · Cited by 325 · see citing works

EpCAM: Structure and function in health and disease

Schnell, U., Cirulli, V., & Giepmans, B. N. G. (2013) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2013.04.018 · Cited by 291 · see citing works

A Rational Strategy for Reducing On-Target Off-Tumor Effects of CD38-Chimeric Antigen Receptors by Affinity Optimization

Drent, E., Themeli, M., Poels, R., de Jong-Korlaar, R., Yuan, H., de Bruijn, J. D., Martens, A. C., Zweegman, S., van de Donk, N. W. C. J., Groen, R. W. J., et al. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.04.024 · Cited by 276 · see citing works

Efficacy of adoptive therapy with tumor-infiltrating lymphocytes and recombinant interleukin-2 in advanced cutaneous melanoma: a systematic review and meta-analysis

Dafni, U., Michielin, O. A., Lluesma, S. M., Tsourti, Z., Polydoropoulou, V., Karlis, D., Besser, M. J., Haanen, J. B. A. G., Svane, I. M., Ohashi, P. S., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz398 · Cited by 264 · see citing works

Driving gene-engineered T cell immunotherapy of cancer

Johnson, L. A., & June, C. H. (2016) · Cell Research · doi:10.1038/cr.2016.154 · Cited by 263 · see citing works

Recent developments of c‐Met as a therapeutic target in hepatocellular carcinoma

Bouattour, M., Raymond, É., Qin, S., Cheng, A., Stammberger, U. M., Locatelli, G., & Faivre, S. J. (2017) · Hepatology · doi:10.1002/hep.29496 · Cited by 260 · see citing works

NKG2D and Its Ligands: “One for All, All for One”

Zingoni, A., Molfetta, R., Fionda, C., Soriani, A., Paolini, R., Cippitelli, M., Cerboni, C., & Santoni, A. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00476 · Cited by 255 · see citing works

Targeting the human epidermal growth factor receptor 2 (HER2) oncogene in colorectal cancer

Siena, S., Bianchi, A. S., Marsoni, S., Hurwitz, H. I., McCall, S. J., Penault-Llorca, F. M., Srock, S., Bardelli, A., & Trusolino, L. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy100 · Cited by 249 · see citing works

"Anomalous" THY-1(+) killer cells in allogeneic and F1-anti-parental mixed leukocyte culture. Relation to natural killer cells and allospecific cytotoxic T lymphocytes

Kärre, K., Seeley, J. K., Eriksson, E., Burton, R., & Kiessling, R. W. (1982) · The Journal of Experimental Medicine · doi:10.1084/jem.156.2.385 · Cited by 241 · see citing works

NKG2D and its ligands in cancer

Dhar, P., & Wu, J. D. (2018) · Current Opinion in Immunology · doi:10.1016/j.coi.2018.02.004 · Cited by 240 · see citing works

Perspectives of tumor-infiltrating lymphocyte treatment in solid tumors

Wang, S., Sun, J., Chen, K., Ma, P., Lei, Q., Xing, S., Cao, Z., Sun, S., Yu, Z., Liu, Y., et al. (2021) · BMC Medicine · doi:10.1186/s12916-021-02006-4 · Cited by 222 · see citing works

Advances in Universal CAR-T Cell Therapy

Lin, H., Cheng, J., Mu, W., Zhou, J., & Zhu, L. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.744823 · Cited by 207 · see citing works

Tumor Infiltrating Lymphocyte (TIL) Therapy for Solid Tumor Treatment: Progressions and Challenges

Zhao, Y., Deng, J. M., Rao, S., Guo, S., Shen, J., Du, F., Wu, X., Chen, Y., Li, M., Chen, M., et al. (2022) · Cancers · doi:10.3390/cancers14174160 · Cited by 207 · see citing works

Impact of Manufacturing Procedures on CAR T Cell Functionality

Watanabe, N., Mo, F., & McKenna, M. K. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.876339 · Cited by 199 · see citing works

Adoptive cellular therapy in solid tumor malignancies: review of the literature and challenges ahead

Kirtane, K., Elmariah, H., Chung, C. H., & Abate‐Daga, D. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002723 · Cited by 198 · see citing works

Tumor-infiltrating lymphocytes: Warriors fight against tumors powerfully

Lin, B., Du, L., Li, H., Zhu, X. M., Cui, L., & Li, X. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110873 · Cited by 185 · see citing works

CAR T‐cell therapy: Full speed ahead

Sermer, D. J., & Brentjens, R. J. (2019) · Hematological Oncology · doi:10.1002/hon.2591 · Cited by 183 · see citing works

Chimeric Antigen Receptor– and TCR-Modified T Cells Enter Main Street and Wall Street

Barrett, D. M., Grupp, S. A., & June, C. H. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1500751 · Cited by 180 · see citing works

Duplication of primate and rodent B7-H3 immunoglobulin V- and C-like domains: divergent history of functional redundancy and exon loss

Ling, V., Wu, P. W., Spaulding, V., Kieleczawa, J., Luxenberg, D. P., Carreno, B. M., & Collins, M. A. (2003) · Genomics · doi:10.1016/s0888-7543(03)00126-5 · Cited by 174 · see citing works

Activating HER2 mutations as emerging targets in multiple solid cancers

Connell, C. M., & Doherty, G. J. (2017) · ESMO Open · doi:10.1136/esmoopen-2017-000279 · Cited by 169 · see citing works

Cell therapies in the clinic

Wang, L. L., Janes, M. E., Kumbhojkar, N., Kapate, N., Clegg, J. R., Prakash, S., Heavey, M. K., Zhao, Z., Anselmo, A. C., & Mitragotri, S. (2021) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10214 · Cited by 162 · see citing works

Stage- and tissue-specific expression of the neu oncogene in rat development.

Kokai, Y., Cohen, J. A., Drebin, J. A., & Greene, M. I. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.23.8498 · Cited by 159 · see citing works

Driving T-cell immunotherapy to solid tumors

Garber, K. (2018) · Nature Biotechnology · doi:10.1038/nbt.4090 · Cited by 155 · see citing works

A review on development of MUC1-based cancer vaccine

Gao, T., Cen, Q., & Lei, H. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110888 · Cited by 152 · see citing works

Off-the-Shelf CAR-NK Cells for Cancer Immunotherapy

Siegler, E. L., Zhu, Y., Wang, P., & Yang, L. (2018) · Cell stem cell · doi:10.1016/j.stem.2018.07.007 · Cited by 150 · see citing works

T-cell-specific deletion of T-cell receptor transgenes allows functional rearrangement of endogenous α- and β-genes

Blüthmann, H., Kisielow, P., Uematsu, Y., Malissen, M., Krimpenfort, P., Berns, A. J. M., von Boehmer, H., & Steinmetz, M. (1988) · Nature · doi:10.1038/334156a0 · Cited by 146 · see citing works

Cell Therapy With TILs: Training and Taming T Cells to Fight Cancer

Kumar, A., Watkins, R., & Vilgelm, A. E. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.690499 · Cited by 145 · see citing works

Colorectal cancer vaccines: Tumor-associated antigens vs neoantigens

Wagner, S., Mullins, C. S., & Linnebacher, M. (2018) · World Journal of Gastroenterology · doi:10.3748/wjg.v24.i48.5418 · Cited by 144 · see citing works

Human GUCY2C-Targeted Chimeric Antigen Receptor (CAR)-Expressing T Cells Eliminate Colorectal Cancer Metastases

Magee, M. S., Abraham, T. S., Baybutt, T. R., Flickinger, J. C., Ridge, N. A., Marszalowicz, G. P., Prajapati, P., Hersperger, A. R., Waldman, S. A., & Snook, A. E. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0362 · Cited by 143 · see citing works

Cost Effectiveness of Chimeric Antigen Receptor T-Cell Therapy in Relapsed or Refractory Pediatric B-Cell Acute Lymphoblastic Leukemia

Lin, J. K., Lerman, B. J., Barnes, J. I., Boursiquot, B. C., Tan, Y. J., Robinson, A. Q. L., Davis, K. L., Owens, D. K., & Goldhaber‐Fiebert, J. D. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.79.0642 · Cited by 143 · see citing works

Safety and efficacy of adoptive cell transfer using autologous tumor infiltrating lymphocytes (LN-145) for treatment of recurrent, metastatic, or persistent cervical carcinoma.

Jazaeri, A. A., Zsíros, E., Amaria, R. N., Artz, A. S., Edwards, R. P., Wenham, R. M., Slomovitz, B. M., Walther, A., Thomas, S. S., Chesney, J. A., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.2019.37.15_suppl.2538 · Cited by 143 · see citing works

miR-153 suppresses IDO1 expression and enhances CAR T cell immunotherapy

Huang, Q., Xia, J., Wang, L., Wang, X., Ma, X., Deng, Q., Lu, Y., Kumar, M., Zhou, Z., Li, L., et al. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-018-0600-x · Cited by 137 · see citing works

Anti‐MUC1 aptamer: A potential opportunity for cancer treatment

Nabavinia, M. S., Gholoobi, A., Charbgoo, F., Nabavinia, M., Ramezani, M., & Abnous, K. (2017) · Medicinal Research Reviews · doi:10.1002/med.21462 · Cited by 136 · see citing works

Mesothelin-targeted CAR-T cell therapy for solid tumors

Klampatsa, A., Dimou, V., & Albelda, S. (2020) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2021.1843628 · Cited by 130 · see citing works

Molecular architecture of the αβ T cell receptor–CD3 complex

Birnbaum, M. E., Berry, R., Hsiao, Y., Chen, Z., Shingú-Vázquez, M., Yu, X., Waghray, D., Fischer, S., McCluskey, J., Rossjohn, J., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1420936111 · Cited by 126 · see citing works

Immunohistochemistry of Carcino-Embryonic Antigen in the Embryo, Fetus and Adult

Nap, M., Møllgård, K., Burtin, P., & Fleuren, G. J. (1988) · Tumor Biology · doi:10.1159/000217555 · Cited by 122 · see citing works

Tebentafusp: First Approval

Dhillon, S. (2022) · Drugs · doi:10.1007/s40265-022-01704-4 · Cited by 116 · see citing works

TCR-T Immunotherapy: The Challenges and Solutions

Liu, Y., Yan, X., Zhang, F., Zhang, X., Tang, F., Han, Z., & Li, Y. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2021.794183 · Cited by 115 · see citing works

Recent Advances in Allogeneic CAR-T Cells

Kim, D. W., & Cho, J. (2020) · Biomolecules · doi:10.3390/biom10020263 · Cited by 110 · see citing works

Phenotype and Function of T Cells Infiltrating Visceral Metastases from Gastrointestinal Cancers and Melanoma: Implications for Adoptive Cell Transfer Therapy

Turcotte, S., Gros, A., Hogan, K., Tran, E., Hinrichs, C. S., Wunderlich, J. R., Dudley, M. E., & Rosenberg, S. A. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1300538 · Cited by 107 · see citing works

Antibody Based EpCAM Targeted Therapy of Cancer, Review and Update

Eyvazi, S., Farajnia, S., Dastmalchi, S., Kanipour, F., Zarredar, H., & Bandehpour, M. (2018) · Current Cancer Drug Targets · doi:10.2174/1568009618666180102102311 · Cited by 107 · see citing works

T-cell-based immunotherapy in colorectal cancer

Feng, M., Zhao, Z., Yang, M., Ji, J., & Zhu, D. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.10.040 · Cited by 107 · see citing works

Cancer Regression in Patients After Transfer of Genetically Engineered Lymphocytes

THIERS, B. H. (2007) · Yearbook of Dermatology and Dermatologic Surgery · doi:10.1016/s0093-3619(08)70664-6 · Cited by 106 · see citing works

Chimeric antigen-receptor T-cell therapy for hematological malignancies and solid tumors: Clinical data to date, current limitations and perspectives

Gauthier, J., & Yakoub‐Agha, I. (2017) · Current Research in Translational Medicine · doi:10.1016/j.retram.2017.08.003 · Cited by 101 · see citing works

Biochemical Markers of Colorectal Cancer – Present and Future

Jelski, W., & Mroczko, B. (2020) · Cancer Management and Research · doi:10.2147/cmar.s253369 · Cited by 100 · see citing works

c-MET Overexpression in Colorectal Cancer: A Poor Prognostic Factor for Survival

Lee, S. J., Lee, J., Park, S. H., Park, J. O., Lim, H. Y., Kang, W. K., Park, Y. S., & Kim, S. T. (2018) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2018.02.013 · Cited by 98 · see citing works

Engineering chimeric antigen receptor-T cells for cancer treatment

Ye, B., Stary, C. M., Li, X., Gao, Q., Kang, C., & Xiong, X. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0814-0 · Cited by 95 · see citing works

HER2: An emerging target in colorectal cancer

Greally, M., Kelly, C. M., & Cercek, A. (2018) · Current Problems in Cancer · doi:10.1016/j.currproblcancer.2018.07.001 · Cited by 94 · see citing works

Hypoxia Selectively Impairs CAR-T Cells In Vitro

Berahovich, R., Liu, X., Zhou, H., Tsadik, E., Xu, S., Golubovskaya, V., & Wu, L. (2019) · Cancers · doi:10.3390/cancers11050602 · Cited by 94 · see citing works

CD28z CARs and Armored CARs

Pegram, H. J., Park, J. H., & Brentjens, R. J. (2014) · The Cancer Journal · doi:10.1097/ppo.0000000000000034 · Cited by 90 · see citing works

Extracellular domain of EpCAM enhances tumor progression through EGFR signaling in colon cancer cells

Liang, K.-H., Tso, H.-C., Hung, S.-H., Kuan, I., Lai, J.-K., Ke, F.-Y., Chuang, Y., Liu, I.-J., Wang, Y., Chen, R., et al. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.06.040 · Cited by 89 · see citing works

Preclinical Evaluation of Chimeric Antigen Receptor–Modified T Cells Specific to Epithelial Cell Adhesion Molecule for Treating Colorectal Cancer

Zhang, B.-L., Li, D., Gong, Y.-L., Huang, Y., Qin, D.-Y., Jiang, L., Liang, X., Yang, X., Gou, H.-F., Wang, Y.-S., et al. (2019) · Human Gene Therapy · doi:10.1089/hum.2018.229 · Cited by 88 · see citing works

Cellular immunotherapies for cancer

Hayes, C. (2020) · Irish Journal of Medical Science (1971 -) · doi:10.1007/s11845-020-02264-w · Cited by 87 · see citing works

Cell Therapy for Colorectal Cancer: The Promise of Chimeric Antigen Receptor (CAR)-T Cells

Aparicio, C., Belver, M., Enríquez, L., Espeso, F., Núñez, L., Sánchez, A., de la Fuente, M. Á., & González‐Vallinas, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222111781 · Cited by 86 · see citing works

HITM-SURE: Hepatic immunotherapy for metastases phase Ib anti-CEA CAR-T study utilizing pressure enabled drug delivery

Katz, S. C., Moody, A. E., Guha, P., Hardaway, J. C., Prince, E. A., LaPorte, J. P., Stancu, M., Slansky, J. E., Jordan, K. R., Schulick, R. D., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001097 · Cited by 83 · see citing works

The co-stimulatory molecule B7-H3 promotes the epithelial-mesenchymal transition in colorectal cancer

Jiang, B., Zhang, T., Liu, F., Sun, Z., Shi, H., Hua, D., & Yang, C. G. (2016) · Oncotarget · doi:10.18632/oncotarget.9035 · Cited by 83 · see citing works

TCR engineered T cells for solid tumor immunotherapy

Zhang, Y., Liu, Z., Wei, W., & Li, Y. (2022) · Experimental Hematology and Oncology · doi:10.1186/s40164-022-00291-0 · Cited by 79 · see citing works

Immunotherapy in gastrointestinal cancer: The current scenario and future perspectives

Abdul-Latif, M., Townsend, K., Dearman, C., Shiu, K., & Khan, K. H. (2020) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2020.102030 · Cited by 78 · see citing works

Results and challenges of immune checkpoint inhibitors in colorectal cancer

Emambux, S., Tachon, G., Junca, A., & Tougeron, D. (2018) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2018.1445222 · Cited by 74 · see citing works

Antitumor activity of NKG2D CAR-T cells against human colorectal cancer cells in vitro and in vivo.

Deng, X., Gao, F., Li, N., Li, Q., Zhou, Y., Yang, T., Cai, Z., Du, P., Chen, F., & Cai, J. (2019) · PubMed Central · Cited by 74 · see citing works

Activating ERBB2/HER2 mutations indicate susceptibility to pan-HER inhibitors in Lynch and Lynch-like colorectal cancer

Kloth, M., Ruesseler, V., Engel, C., Koenig, K., Peifer, M., Mariotti, E., Kuenstlinger, H., Florin, A., Rommerscheidt-Fuss, U., Koitzsch, U., et al. (2016) · Gut · doi:10.1136/gutjnl-2014-309026 · Cited by 73 · see citing works

T-cell Responses in the Microenvironment of Primary Renal Cell Carcinoma—Implications for Adoptive Cell Therapy

Andersen, R. S., Westergaard, M. C. W., Kjeldsen, J. W., Müller, A., Pedersen, N. W., Hadrup, S. R., Met, Ö., Seliger, B., Kromann‐Andersen, B., Hasselager, T., et al. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-17-0467 · Cited by 73 · see citing works

From humble beginnings to success in the clinic: Chimeric antigen receptor-modified T-cells and implications for immunotherapy

Firor, A. E., Jares, A., & Ma, Y. (2015) · Experimental Biology and Medicine · doi:10.1177/1535370215584936 · Cited by 71 · see citing works

Molecular Landscape of <i>ERBB2/ERBB3</i> Mutated Colorectal Cancer

Loree, J. M., Bailey, A. M., Johnson, A. M., Yu, Y., Wu, W., Bristow, C. A., Davis, J. S., Shaw, K. R., Broaddus, R., Banks, K. C., et al. (2018) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djy067 · Cited by 68 · see citing works

Chimeric Antigen Receptor T-Cell Therapy for Colorectal Cancer

Sur, D. G., Havasi, A. D., Cainap, C. I., Samaşcă, G., Burz, C. C., Bălăcescu, O., Lupan, I., Deleanu, D. M., & Irimie, A. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9010182 · Cited by 67 · see citing works

Regression of a disseminated syngeneic solid tumor by systemic transfer of lymphoid cells expanded in interleukin 2.

Eberlein, T. J., Rosenstein, M., & Rosenberg, S. A. (1982) · The Mouseion at the JAXlibrary (Jackson Laboratory) · Cited by 67 · see citing works

CAR-T cells for Colorectal Cancer: Target-selection and strategies for improved activity and safety

Li, H., Yang, C., Cheng, H., Huang, S., & Zheng, Y. (2021) · Journal of Cancer · doi:10.7150/jca.50509 · Cited by 59 · see citing works

The c-Met receptor: Implication for targeted therapies in colorectal cancer

Qamsari, E. S., Ghaderi, S. S., Zarei, B., Dorostkar, R., Bagheri, S., Jadidi‐Niaragh, F., Somi, M. H., & Yousefi, M. (2017) · Tumor Biology · doi:10.1177/1010428317699118 · Cited by 59 · see citing works

Combining Oncolytic Viruses with Chimeric Antigen Receptor T Cell Therapy

McGrath, K. V., & Dotti, G. (2020) · Human Gene Therapy · doi:10.1089/hum.2020.278 · Cited by 57 · see citing works

Cell Fate Reprogramming in the Era of Cancer Immunotherapy

Zimmermannova, O., Caiado, I., Ferreira, A. G., & Pereira, C.-F. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.714822 · Cited by 56 · see citing works

Emerging Strategies in TCR-Engineered T Cells

Fang, W., Cheng, X., Xue, J. Z., & Xue, S. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.850358 · Cited by 54 · see citing works

CAR T-cell therapies in China: rapid evolution and a bright future

Hu, Y., Feng, J., Gu, T., Wang, L., Wang, Y., Zhou, L., Hong, R., Yin, E. T. S., Zhang, M., Lu, P., et al. (2022) · The Lancet Haematology · doi:10.1016/s2352-3026(22)00291-5 · Cited by 54 · see citing works

Durable Complete Responses in Heavily Pretreated Patients with metastatic Melanoma Using T-Cell Transfer Immunotherapy

Eberlein, T. J. (2012) · Yearbook of Surgery · doi:10.1016/j.ysur.2011.09.015 · Cited by 53 · see citing works

Chimeric Antigen Receptor–modified T Cells Repressed Solid Tumors and Their Relapse in an Established Patient-derived Colon Carcinoma Xenograft Model

Teng, R., Zhao, J., Zhao, Y., Gao, J., Li, H., Zhou, S., Wang, Y., Sun, Q., Lin, Z., Yang, W., et al. (2018) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000251 · Cited by 53 · see citing works

Breaking Bottlenecks for the TCR Therapy of Cancer

Gaissmaier, L., Elshiaty, M., & Christopoulos, P. (2020) · Cells · doi:10.3390/cells9092095 · Cited by 52 · see citing works

Study protocol for THINK: a multinational open-label phase I study to assess the safety and clinical activity of multiple administrations of NKR-2 in patients with different metastatic tumour types

Lonez, C., Verma, B., Hendlisz, A., Aftimos, P. G., Awada, A. H., Neste, E. V. D., Catala, G., Machiels, J., Piette, F., Brayer, J. B., et al. (2017) · BMJ Open · doi:10.1136/bmjopen-2017-017075 · Cited by 49 · see citing works

CD133: An emerging prognostic factor and therapeutic target in colorectal cancer

Akbari, M., Shomali, N., Faraji, A., Shanehbandi, D., Asadi, M., Mokhtarzadeh, A., Shabani, A., & Baradaran, B. (2019) · Cell Biology International · doi:10.1002/cbin.11243 · Cited by 49 · see citing works

The old CEACAMs find their new role in tumor immunotherapy

Han, Z.-W., Lyv, Z.-W., Cui, B., Wang, Y., Cheng, J.-T., Zhang, Y., Cai, W.-Q., Zhou, Y., Ma, Z., Wang, X.-W., et al. (2020) · Investigational New Drugs · doi:10.1007/s10637-020-00955-w · Cited by 49 · see citing works

Engineering strategies for broad application of TCR-T- and CAR-T-cell therapies

Watanabe, K., & Nishikawa, H. (2021) · International Immunology · doi:10.1093/intimm/dxab052 · Cited by 49 · see citing works

Mechanisms of resistance to CAR T cell therapies

Singh, N., Orlando, E. J., Xu, J., Xu, J., Binder, Z. A., Collins, M. A., O’Rourke, D. M., & Melenhorst, J. J. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.12.002 · Cited by 47 · see citing works

Checkpoints and beyond – Immunotherapy in colorectal cancer

Gutting, T., Burgermeister, E., Härtel, N., & Ebert, M. P. A. (2018) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2018.04.003 · Cited by 46 · see citing works

Neoantigen-targeted TCR-T cell therapy for solid tumors: How far from clinical application

Xu, R., Du, S., Zhu, J., Meng, F., & Liu, B. (2022) · Cancer Letters · doi:10.1016/j.canlet.2022.215840 · Cited by 45 · see citing works

Diffuse mesothelin expression leads to worse prognosis through enhanced cellular proliferation in colorectal cancer

Inoue, S., Tsunoda, T., Riku, M., Ito, H., Inoko, A., Murakami, H., Ebi, M., Ogasawara, N., Pastan, I. H., Kasugai, K., et al. (2020) · Oncology Letters · doi:10.3892/ol.2020.11290 · Cited by 42 · see citing works

The c-MET oncoprotein: Function, mechanisms of degradation and its targeting by novel anti-cancer agents

Park, K. C., & Richardson, D. R. (2020) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2020.129650 · Cited by 40 · see citing works

The most reliable surface marker for the identification of colorectal cancer stem‐like cells: A systematic review and meta‐analysis

Abbasian, M., Mousavi, E., Arab‐Bafrani, Z., & Sahebkar, A. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.27619 · Cited by 38 · see citing works

Clinical Grade Manufacture of CYAD-101, a NKG2D-based, First in Class, Non–Gene-edited Allogeneic CAR T-Cell Therapy

Michaux, A., Mauën, S., Breman, E., Dheur, M.-S., Twyffels, L., Saerens, L., Jacques-Hespel, C., Gauthy, E., Agaugué, S., Gilham, D. E., et al. (2022) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000413 · Cited by 33 · see citing works

New chimeric antigen receptor design for solid tumors

Wang, Y., Luo, F., Yang, J., Zhao, C., & Chu, Y. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01934 · Cited by 32 · see citing works

The prognostic role of tumor associated glycoprotein 72 (TAG-72) in stage II and III colorectal adenocarcinoma

Cho, J., Kim, K., Kim, H. C., Lee, W. Y., Kang, W. K., Park, Y. S., & Ha, S. Y. (2018) · Pathology - Research and Practice · doi:10.1016/j.prp.2018.10.024 · Cited by 30 · see citing works

HER-2 and HER-3 expression in liver metastases of patients with colorectal cancer

Styczen, H., Nagelmeier, I., Beißbarth, T., Nietert, M. M., Homayounfar, K., Sprenger, T., Boczek, U., Stanek, K., Kitz, J., Wolff, H. A., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.3527 · Cited by 29 · see citing works

Current status and regulatory perspective of chimeric antigen receptor-modified T cell therapeutics

Kim, M.-G., Kim, D., Suh, S., Park, Z., Choi, M. J., & Oh, Y. (2016) · Archives of Pharmacal Research · doi:10.1007/s12272-016-0719-7 · Cited by 29 · see citing works

The Landscape of Tumor-Specific Antigens in Colorectal Cancer

Bakarurraini, N. A. A. R., Mutalib, N. A., Jamal, R., & Abu, N. (2020) · Vaccines · doi:10.3390/vaccines8030371 · Cited by 28 · see citing works

Abstract CT056: Durable complete responses to adoptive cell transfer using tumor infiltrating lymphocytes (TIL) in non-small cell lung cancer (NSCLC): A phase I trial

Creelan, B., Wang, C., Teer, J. K., Toloza, E. M., Mullinax, J. E., Yao, J., Koomen, J. M., Kim, S., Chiappori, A., Saller, J. J., et al. (2020) · Cancer Research · doi:10.1158/1538-7445.am2020-ct056 · Cited by 27 · see citing works

Recent advances in T‐cell immunotherapy for haematological malignancies

Rouce, R. H., Sharma, S., Huynh, M., & Heslop, H. E. (2016) · British Journal of Haematology · doi:10.1111/bjh.14470 · Cited by 25 · see citing works

TCR gene-engineered cell therapy for solid tumors

Tan, E. S., Gakhar, N., & Kirtane, K. (2021) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2021.101285 · Cited by 23 · see citing works

Selective expression of carcinoembryonic antigen promoter in cancer cell lines

Fichera, A., Michelassi, F., & Arenas, R. B. (1998) · Diseases of the Colon & Rectum · doi:10.1007/bf02236263 · Cited by 22 · see citing works

GUCY2C as a biomarker to target precision therapies for patients with colorectal cancer

Lisby, A., Flickinger, J. C., Bashir, B., Weindorfer, M., Shelukar, S., Crutcher, M. M., Snook, A. E., & Waldman, S. A. (2021) · Expert Review of Precision Medicine and Drug Development · doi:10.1080/23808993.2021.1876518 · Cited by 18 · see citing works

WITHDRAWNPreprint

Muungo, L. (2020) · doi:10.31234/osf.io/ya2u9 · Cited by 14 · see citing works

Adoptive T-cell immunotherapy in digestive tract malignancies: Current challenges and future perspectives

Mandriani, B., Pellè, E., Pezzicoli, G., Strosberg, J., Abate‐Daga, D., Guarini, A., Cives, M., & Porta, C. (2021) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2021.102288 · Cited by 13 · see citing works

CAR-T cells: the Chinese experience

Wang, L.-Q., Yin, E. T. S., Zhao, H., Ni, F., Hu, Y., & Huang, H. (2020) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2020.1790521 · Cited by 7 · see citing works

Preclinical Evaluation of Chimeric Antigen Receptor–Modified T Cells Specific to Epithelial Cell Adhesion Molecule for Treating Colorectal Cancer

Wang, W. (2019) · Human Gene Therapy · doi:10.1089/hum.2019.178 · Cited by 7 · see citing works

Advancements in immunotherapy for colorectal cancer treatment: a comprehensive review of strategies, challenges, and future prospective

Kaviarasan, V., Das, A., Deka, D., Saha, B., Banerjee, A., Sharma, N. R., Duttaroy, A. K., & Pathak, S. (2024) · International Journal of Colorectal Disease · doi:10.1007/s00384-024-04790-w · Cited by 45 · see citing works

Lighting up the fire in the microenvironment of cold tumors: a major challenge to improve cancer immunotherapy

Benoit, A., Vogin, G., Duhem, C., Berchem, G., & Janji, B. (2023) · Cells · doi:10.3390/cells12131787 · Cited by 39 · see citing works

Current and Future Trends of Colorectal Cancer Treatment: Exploring Advances in Immunotherapy

Nikolouzakis, T. K., Chrysos, E., Docea, A. O., Fragkiadaki, P., Souglakos, J., Tsiaoussis, J., & Tsatsakis, A. (2024) · Cancers · doi:10.3390/cancers16111995 · Cited by 37 · see citing works

Cell Therapy as Target Therapy against Colon Cancer Stem Cells

Garza Treviño, E. N., Quiroz Reyes, A. G., Rojas Murillo, J. A., de la Garza Kalife, D. A., Delgado Gonzalez, P., Islas, J. F., Estrada Rodriguez, A. E., & Gonzalez Villarreal, C. A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24098163 · Cited by 24 · see citing works

Clinical application of cytokine-induced killer (CIK) cell therapy in colorectal cancer: Current strategies and future challenges

Li, C. M. Y., Li, R., Drew, P. A., Price, T. J., Smith, E., Maddern, G. J., Tomita, Y., & Fenix, K. A. (2023) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2023.102665 · Cited by 24 · see citing works

NKG2D Fine-Tunes the Local Inflammatory Response in Colorectal Cancer

Curio, S., Lin, W., Bromley, C. P., McGovern, J. L., Triulzi, C., Jonsson, G., Ghislat, G., Zelenay, S., & Guerra, N. (2023) · Cancers · doi:10.3390/cancers15061792 · Cited by 8 · see citing works

Research advances on TIL therapy for colorectal cancer

Jiang, J., Shu, W., & Yao, Q. (2024) · Clinical & Translational Oncology · doi:10.1007/s12094-024-03530-4 · Cited by 5 · see citing works

Current and Future Directions in Immunotherapy for Gastrointestinal Malignancies

Lewis, C. R., Samhouri, Y., Sherry, C., Dadgar, N., Raj, M. S., & Wagner, P. L. (2025) · International Journal of Translational Medicine · doi:10.3390/ijtm5030033 · Cited by 3 · see citing works

Novel Immunotherapy Approaches in Colorectal Cancer

Afra, F., Mohammadi, S., Farid, A. S., Moghaddam, S., Meftah, E., Mortezaei, N. T., & Fathi, M. (2024) · Interdisciplinary cancer research · doi:10.1007/16833_2024_398 · Cited by 1 · see citing works

Diagnostic Advances and Novel Therapeutics in Peritoneal Metastasis

Sigler, G., Murtha, J. A., & Varley, P. R. (2025) · Surgical Oncology Clinics of North America · doi:10.1016/j.soc.2024.12.005

Investigational CRISPR-Cas9-edited T cells for metastatic colorectal cancer treatment: Clinical insights for future development

Lou, E. M. S., Foo, J., & Leder, K. (2026) · Molecular Therapy Oncology · doi:10.1016/j.omton.2026.201139

Next-generation of mesothelin-targeted CAR-T cells secreting anti-PD-L1 scFv for potent immunotherapy against 3D patient-derived colorectal cancer organoids

Phanthaphol, N., Kanoksing, P., Riansuwan, W., Prapasrivorakul, S., Ovartchaiyapong, P., Mongkhonsupphawan, A., Phumphuang, S., Junking, M., Thuwajit, P., Yenchitsomanus, P., et al. (2026) · BMC Medicine · doi:10.1186/s12916-026-05004-6

Targeting of tripartite neuron-cancer-immune cell crosstalk augments response to chemotherapy and immunotherapy

Jain, D., Pandey, N., Jha, S. K., Sinha, S., Singh, R., Alam, J., Aggarwal, B., Chauhan, N., Acharya, A., Anu, P. V., et al. (2026) · Cell Reports Medicine · doi:10.1016/j.xcrm.2026.102994

Adoptive cell therapy in colorectal cancer: Advances in chimeric antigen receptor T cells

Chen, M., Wang, C., Wang, Y., & Shi, M. (2025) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v17.i7.106723 · Cited by 7 · see citing works

Adoptive Cell Transfer: Is it a Promising Immunotherapy for Colorectal Cancer?

Fan, J., Shang, D., Han, B., Song, J. J., Chen, H., & Yang, J. (2018) · Theranostics · doi:10.7150/thno.29035 · Cited by 66 · see citing works

Adoptive T-Cell Therapy in Advanced Colorectal Cancer: A Systematic Review

Juat, D. J., Hachey, S. J., Billimek, J., Rosario, M. P. D., Nelson, E. L., Hughes, C. C. W., & Zell, J. A. (2022) · The Oncologist · doi:10.1093/oncolo/oyab038 · Cited by 27 · see citing works

Adoptive T-Cell Therapy as a Therapeutic Strategy for Advanced Colorectal Cancer

Juat, D. J. (2020) · eScholarship (California Digital Library)

Comprehensive assessment of the feasibility of adoptive cell therapy in colorectal carcinoma

Rodrigo, B. N., Viganó, S., Gannon, P. O., Baumgärtner, P., Maisonneuve, C., Sempoux, C. L., Sauvain, M., Hahnloser, D., Hübner, M., Demartines, N., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw378.42 · Cited by 1 · see citing works